Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 51Genitourinary 18Thoracic 13Gynecologic 7CNS 5Other solid neoplasm 4Head & Neck 3Tumor-Agnostic 2Gastrointestinal 2

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Klatskin Tumor 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 300Fluorouracil 272Bevacizumab 237Gemcitabine 236Leucovorin 212Capecitabine 207pembrolizumab 201Nivolumab 158Irinotecan 158Cisplatin 150Specimen Handling 144Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 118Paclitaxel 109durvalumab 107Cetuximab 104Radiotherapy 99atezolizumab 94Drug Therapy 94Biopsy 93tislelizumab 81Albumin-Bound Paclitaxel 81Taxes 74Folfox protocol 68lenvatinib 67Carboplatin 66regorafenib 60Blood Specimen Collection 60sintilimab 54Ipilimumab 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
sacituzumab govitecan × Gastrointestinal × 1 year × Clear all
NCT06178588 2026-02-24

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

University of Kansas Medical Center

Phase 2 Active not recruiting
15 enrolled
Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

NCT06065371 2025-12-19

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Henry Ford Health System

Phase 1 Recruiting
20 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡